Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin and Irinotecan in recurrent malignant glioma
NCT01144988Phase 2Unknown
- Sponsor
- Medical University of Innsbruck
- Start
- Mar 2010
- Primary completion
- Mar 2013
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in malignant glioma, sponsored by Medical University of Innsbruck. Primary endpoint: Response Rate, Objective Response Rate, Objective Response Duration at 3 years. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT01144988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01144988.